EMD 2.94% 3.3¢ emyria limited

Ann: Company Overview and Strategic Update, page-3

  1. 293 Posts.
    lightbulb Created with Sketch. 62
    They had to halt the trial due to issues with consistent dosages in the capsules.

    There now seems to be a pivot to MDMA therapies as the primary focus.
 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.